1176 / 1816
Use of extended adjuvant endocrine therapy
• Higher stage at diagnosis
• Limited or absent toxicity
• Absence of life-threatening co-morbidities
• Younger age
• Patient preference
• Biomarkers for late recurrence?
19-9-2017